aica ribonucleotide has been researched along with Ventricular Dysfunction, Left in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benham, A; Entman, ML; Kaelber, JT; Kim, E; Nam, DH; Park, HK; Reineke, EL; Soibam, B; Suh, JH; Taegtmeyer, H; Taffet, GE | 1 |
| Asakura, M; Asanuma, H; Fujita, M; Ito, S; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Mochizuki, N; Ogai, A; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M | 1 |
2 other study(ies) available for aica ribonucleotide and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Transient activation of AMPK preceding left ventricular pressure overload reduces adverse remodeling and preserves left ventricular function.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Cardiomegaly; Hypoglycemic Agents; Male; Mice; Mice, Knockout; Myocytes, Cardiac; Nuclear Receptor Coactivator 2; Ribonucleotides; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2019 |
Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; Cells, Cultured; Disease Progression; Dogs; Drug Evaluation, Preclinical; Fibrosis; Gene Expression Regulation; Heart Failure; Insulin Resistance; Metformin; Myocytes, Cardiac; Natriuretic Peptides; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Ribonucleotides; Transforming Growth Factor beta1; Ultrasonography; Ventricular Dysfunction, Left | 2009 |